Comparing of Gemphire Therapeutics Inc. (GEMP) and Ardelyx Inc. (NASDAQ:ARDX)

As Biotechnology companies, Gemphire Therapeutics Inc. (NASDAQ:GEMP) and Ardelyx Inc. (NASDAQ:ARDX) are our subject to compare. And more specifically their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gemphire Therapeutics Inc. N/A 0.00 23.64M -2.11 0.00
Ardelyx Inc. 2.61M 79.48 91.30M -0.96 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Gemphire Therapeutics Inc. and Ardelyx Inc.

Profitability

Table 2 represents Gemphire Therapeutics Inc. (NASDAQ:GEMP) and Ardelyx Inc. (NASDAQ:ARDX)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Gemphire Therapeutics Inc. 0.00% -211% -99.4%
Ardelyx Inc. -3,498.08% -37.2% -29%

Liquidity

The Current Ratio of Gemphire Therapeutics Inc. is 3.3 while its Quick Ratio stands at 3.3. The Current Ratio of rival Ardelyx Inc. is 12.8 and its Quick Ratio is has 12.8. Ardelyx Inc. is better equipped to clear short and long-term obligations than Gemphire Therapeutics Inc.

Institutional and Insider Ownership

The shares of both Gemphire Therapeutics Inc. and Ardelyx Inc. are owned by institutional investors at 26.1% and 85.1% respectively. About 23.61% of Gemphire Therapeutics Inc.’s share are held by insiders. On the other hand, insiders held about 1.1% of Ardelyx Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Gemphire Therapeutics Inc. 15.83% 29.91% 16.81% -4.14% -80.14% 71.63%
Ardelyx Inc. 12.69% 39.52% 6.55% -34.16% -45.23% 63.69%

For the past year Gemphire Therapeutics Inc. has stronger performance than Ardelyx Inc.

Summary

On 6 of the 9 factors Ardelyx Inc. beats Gemphire Therapeutics Inc.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH). It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. The company is headquartered in Livonia, Michigan.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.